Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 747.31M |
| Revenue (ttm) | 83.69M |
| Net Income (ttm) | -244.79M |
| Shares Out | 76.88M |
| EPS (ttm) | -2.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,566,225 |
| Open | 9.84 |
| Previous Close | 9.76 |
| Day's Range | 9.00 - 9.91 |
| 52-Week Range | 8.18 - 29.56 |
| Beta | 2.34 |
| Analysts | Strong Buy |
| Price Target | 28.29 (+191.05%) |
| Earnings Date | Oct 9, 2025 |
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials f... [Read more]
Financial Performance
In 2024, Nurix Therapeutics's revenue was $54.55 million, a decrease of -29.15% compared to the previous year's $76.99 million. Losses were -$193.57 million, 34.5% more than in 2023.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price target is $28.29, which is an increase of 191.05% from the latest price.
News
Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones
Nurix Therapeutics maintains a Strong Buy rating, driven by promising progress with its oral BTK degrader bexobrutideg for relapsed/refractory CLL. NRIX plans to initiate a pivotal single-arm phase 2 ...
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Presentation of preclinical data from novel IRAK4 protein degrader, GS-6791, discovered in Nurix's ongoing research collaboration with Gilead Sciences
Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call P...
Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Baird Global Healthcare Conference 2025 September 9, 2025 10:50 AM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participant...
Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Nurix Therapeutics, Inc. (NASDAQ:NRIX) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference ...
Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Arthur Sands - CEO, President & Director Conference ...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...
Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors
NRIX's Bexobrutideg shows impressive ORR for refractory CLL/WM. I believe this positions it as a potential best-in-class BTK degrader in a sizable TAM. Nurix Therapeutics also works with other big pha...
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and W...
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...
Sanofi Exercises License Extension Option to Nurix's STAT6 Program
STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi ...
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targe...
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targe...
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targe...
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs
Nurix's DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company's proprietary DNA encoded library data
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour
Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential
FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $...
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app...
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15...
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this...
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of tar...